ABSTRACT
AIMS: Bradyarrhythmia following heart transplantation is common-â¼7.5-24% of patients require permanent pacemaker (PPM) implantation. While overall mortality is similar to their non-paced counterparts, the effects of chronic right ventricular pacing (CRVP) in heart transplant patients have not been studied. We aim to examine the effects of CRVP on heart failure and mortality in heart transplant patients. METHODS AND RESULTS: Records of heart transplant recipients requiring PPM at St Vincent's Hospital, Sydney, Australia between January 1990 and January 2015 were examined. Patient's without a right ventricular (RV) pacing lead or a follow-up time of <1 year were excluded. Patients with pre-existing abnormal left ventricular function (<50%) were analysed separately. Patients were grouped by pacing dependence (100% pacing dependent vs. non-pacing dependent). The primary endpoint was clinical or echocardiographic heart failure (<35%) in the first 5 years post-PPM. Thirty-three of 709 heart transplant recipients were studied. Two patients had complete RV pacing dependence, and the remaining 31 patients had varying degrees of pacing requirement, with an underlying ventricular escape rhythm. The primary endpoint occurred significantly more in the pacing-dependent group; 2 (100%) compared with 2 (6%) of the non pacing dependent group (P < 0.0001 by log-rank analysis, HR = 24.58). Non-pacing-dependent patients had reversible causes for heart failure, unrelated to pacing. In comparison, there was no other cause of heart failure in the pacing-dependent group. CONCLUSIONS: Permanent atrioventricular block is rare in the heart transplant population. We have demonstrated CRVP as a potential cause of accelerated graft failure in pacing-dependent heart transplant patients.
Subject(s)
Atrioventricular Block/physiopathology , Cardiac Pacing, Artificial/adverse effects , Heart Failure/mortality , Heart Transplantation , Pacemaker, Artificial/adverse effects , Primary Graft Dysfunction/physiopathology , Adult , Australia , Bradycardia/etiology , Bradycardia/therapy , Cardiac Pacing, Artificial/methods , Echocardiography , Female , Follow-Up Studies , Heart Failure/etiology , Heart Ventricles/physiopathology , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Retrospective Studies , Ventricular Dysfunction, Left/physiopathologyABSTRACT
BACKGROUND: Both implantable cardioverter defibrillators (ICDs) and left ventricular assist devices (LVADs) have a positive impact on survival in the heart failure population. We sought to determine whether these positive effects on survival are additive or whether LVAD therapy supersedes ICD therapy. METHOD: We analyzed survival data of patients implanted with nonpulsatile LVADs between October 2004 and March 2013. Survival in patients with ICDs (n = 64) was compared to those without ICDs (n = 36). Patients exited the study at the time of heart transplantation or death. RESULTS: A total of 100 patients underwent LVAD implantation during this time. Patients had a mean follow-up time of 364 ± 295 days. Death occurred in 15 (38%) patients in the no ICD group versus 18 (30%) in the ICD group. Univariate analysis demonstrated a marginal early survival benefit at up to 1 year post-LVAD implant in the ICD cohort; however, at time points greater than 1 year there was no statistically significant benefit in ICD therapy in LVAD patients (P = 0.56). Multivariate analysis did not show any significant predictor of survival. There were no patients who died of sudden cardiac death. There was no significant difference in the time to heart transplantation (443 days ± 251 no ICD vs 372 days ± 277 ICD, P = 0.37). CONCLUSION: The benefit of ICD therapy in the setting of continuous flow LVAD therapy is uncertain. Although prolonged ventricular arrhythmias (VAs) may potentially impact on patient survival, LVAD therapy is beneficial in prevention of sudden cardiac death due to VAs.
Subject(s)
Defibrillators, Implantable , Heart Failure/mortality , Heart Failure/therapy , Heart-Assist Devices , Adult , Female , Humans , Male , Middle Aged , Retrospective Studies , Survival RateABSTRACT
We present a case of a young patient, whose first manifestation of isolated ventricular noncompaction (IVNC) was sudden cardiac arrest precipitated by ventricular fibrillation. Furthermore we had the rare opportunity to record the onset of subsequent episodes of ventricular fibrillation-with discussion on the mechanisms of ventricular arrhythmias in IVNC.
Subject(s)
Heart Arrest/diagnosis , Heart Arrest/etiology , Isolated Noncompaction of the Ventricular Myocardium/complications , Isolated Noncompaction of the Ventricular Myocardium/diagnosis , Ventricular Fibrillation/diagnosis , Ventricular Fibrillation/etiology , Adult , Death, Sudden, Cardiac/etiology , Death, Sudden, Cardiac/prevention & control , Diagnosis, Differential , Heart Arrest/prevention & control , Humans , Isolated Noncompaction of the Ventricular Myocardium/prevention & control , Male , Treatment Outcome , Ventricular Fibrillation/prevention & controlSubject(s)
Autoimmune Diseases of the Nervous System/diagnosis , Autonomic Nervous System Diseases/diagnosis , Bradycardia/etiology , Hypotension, Orthostatic/etiology , Adult , Autoimmune Diseases of the Nervous System/complications , Autoimmune Diseases of the Nervous System/drug therapy , Autonomic Nervous System Diseases/complications , Autonomic Nervous System Diseases/drug therapy , Humans , Male , Young AdultABSTRACT
BACKGROUND: Nonpulsatile left ventricular assist devices (LVADs) are increasingly used for treatment of refractory heart failure. A majority of such patients have implanted cardiac devices, namely implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy-pacemaker (CRT-P) or cardiac resynchronization therapy-defibrillator (CRT-D) devices. However, potential interactions between LVADs and cardiac devices in this category of patients remain unknown. METHODS: We reviewed case records and device logs of 15 patients with ICDs or CRT-P or CRT-D devices who subsequently had implantation of a VentrAssist LVAD (Ventracor Ltd., Chatswood, Australia) as destination therapy or bridge to heart transplantation. Pacemaker and ICD lead parameters before and after LVAD implant were compared. In addition, ventricular tachyarrhythmia event logs and potential electromagnetic interference reports were evaluated. RESULTS: Right ventricular (RV) sensing decreased in the first 6 months post-LVAD. Mean R-wave amplitude preimplant was 10.9 +/- 5.25 mV compared with 7.2 +/- 3.4 mV during follow-up (P = 0.02). RV impedance also decreased from 642 +/- 240 ohms at baseline to 580 +/- 212 ohms at follow-up (P = 0.007). There was a significant increase in RV stimulation threshold following implantation of the LVAD from 0.8 +/- 0.6 V at baseline to 1.4 +/- 1.0 V in the first 6 months postimplant (P = 0.01). A marked increase in ventricular tachyarrhythmia burden was observed in three patients. One patient displayed electromagnetic interference between the LVAD and defibrillator, resulting in inappropriate defibrillation therapy. CONCLUSIONS: LVADs have a definite impact on cardiac devices in respect with alteration of lead parameters, ventricular tachyarrhythmias, and electromagnetic interference.
Subject(s)
Defibrillators, Implantable/adverse effects , Heart-Assist Devices/adverse effects , Pacemaker, Artificial/adverse effects , Ventricular Fibrillation/diagnosis , Ventricular Fibrillation/etiology , Adolescent , Adult , Aged , Equipment Failure , Equipment Failure Analysis , Female , Humans , Male , Middle Aged , Retrospective Studies , Treatment Outcome , Young AdultABSTRACT
Only a few case reports of Brugada pattern ECG changes caused by electrolyte disturbance exist in the literature, all of which lack adequate electrophysiological exclusion (or inclusion) of an underlying Brugada syndrome. This report describes a case of an otherwise healthy 38-year-old man who presented to the hospital with diabetic ketoacidosis, profound electrolyte disturbance, and Brugada pattern ECG changes. Subsequent flecanide drug challenge and electrophysiological studies ruled out an underlying Brugada syndrome.
Subject(s)
Bundle-Branch Block/diagnosis , Electrocardiography , Water-Electrolyte Imbalance/complications , Adult , Bundle-Branch Block/complications , Diabetic Ketoacidosis/complications , Diabetic Ketoacidosis/physiopathology , Humans , Male , Water-Electrolyte Imbalance/physiopathologyABSTRACT
This report describes ventricular tachycardia, likely to have been torsade de pointes, following ingestion of the non-sedating antihistamine loratadine. Documentation of the arrhythmia was made possible by the automatic electrogram storage facility of an implanted defibrillator in a patient with no prior history of cardiac arrhythmia.